[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.129.96. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Correspondence
February 2010

Successful Use of Mizoribine to Treat Recurrent Corticosteroid-Resistant Palpable Purpura in a Patient With Henoch-Schönlein Purpura Nephritis

Author Affiliations

Author Affiliations: Departments of Dermatology (Drs Kawakami and Soma) and Internal Medicine, Division of Nephrology and Hypertension (Drs Shirai and Kimura), St Marianna University School of Medicine, Kawasaki, Japan.

Arch Dermatol. 2010;146(2):212-213. doi:10.1001/archdermatol.2009.371

Mizoribine is a newly developed immunosuppressive agent with few toxic effects.1 The pharmacologic effects of mizoribine are similar to those of another purine biosynthesis inhibitor, mycophenolate mofetil. Published studies have shown positive effects of mizoribine and a favorable safety profile for its use in treating nephrotic syndrome,2 IgA nephropathy,3 and lupus nephritis.1

First Page Preview View Large
First page PDF preview
First page PDF preview
×